Company / Cash & Equivalents
Outlook Therapeutics, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$8.1M
FY2025
5-year range
$2.4M / $12.5M
FY2021-FY2025
Trend
-35.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$8M in FY2025 with a 5-year CAGR of -8.4%.
Remained stable around $8M over the past 6 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -8.4%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -8.4%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 35.5% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.1M | -35.5% |
| FY2020 | $12.5M | +56.4% |
| FY2019 | $8.0M | +151.6% |
| FY2018 | $3.2M | +35.4% |
| FY2017 | $2.4M | -74.1% |
| FY2016 | $9.1M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026